{"id":554,"date":"2026-02-28T11:56:04","date_gmt":"2026-02-28T11:56:04","guid":{"rendered":"https:\/\/heartcareforyou.in\/blog\/triglycerides-definition-clinical-context-and-cardiology-overview\/"},"modified":"2026-02-28T11:56:04","modified_gmt":"2026-02-28T11:56:04","slug":"triglycerides-definition-clinical-context-and-cardiology-overview","status":"publish","type":"post","link":"https:\/\/heartcareforyou.in\/blog\/triglycerides-definition-clinical-context-and-cardiology-overview\/","title":{"rendered":"Triglycerides: Definition, Clinical Context, and Cardiology Overview"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Triglycerides Introduction (What it is)<\/h2>\n\n\n\n<p>Triglycerides are a type of lipid (fat) made of glycerol plus three fatty acids.<br\/>\nThey are both a circulating biomarker measured on a lipid panel and a stored energy source in adipose (fat) tissue.<br\/>\nIn cardiology, Triglycerides are commonly encountered during cardiovascular risk assessment and metabolic evaluation.<br\/>\nThey are discussed alongside cholesterol fractions (low-density lipoprotein cholesterol and high-density lipoprotein cholesterol) in dyslipidemia.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why Triglycerides matters in cardiology (Clinical relevance)<\/h2>\n\n\n\n<p>Triglycerides matter in cardiology because they often signal broader cardiometabolic risk. Elevated Triglycerides can cluster with insulin resistance, type 2 diabetes, obesity, and metabolic syndrome\u2014conditions that raise the likelihood of atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease, ischemic stroke, and peripheral artery disease.<\/p>\n\n\n\n<p>From a physiology standpoint, Triglycerides circulate within triglyceride-rich lipoproteins (for example, very-low-density lipoproteins and chylomicrons). When these particles are present in excess, their \u201cremnant\u201d particles can contribute to atherogenesis (plaque formation) because many remnants contain apolipoprotein B (apoB), a marker of atherogenic particle number. In practice, Triglycerides can therefore add context to the lipid profile, particularly when low-density lipoprotein cholesterol (LDL-C) appears acceptable but other features suggest residual risk.<\/p>\n\n\n\n<p>Triglycerides also matter for diagnostic clarity. Marked elevations can interfere with common laboratory calculations (such as calculated LDL-C), can appear in secondary conditions (hypothyroidism, kidney disease, uncontrolled diabetes, certain medications), and can point toward inherited disorders of lipoprotein metabolism. Very high Triglycerides are additionally associated with risk of acute pancreatitis, which\u2014while not primarily a cardiac condition\u2014can complicate cardiovascular care by causing systemic inflammation, hemodynamic instability, and interruptions to chronic cardiometabolic therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Classification \/ types \/ variants<\/h2>\n\n\n\n<p>Triglycerides are not a disease entity by themselves, but clinical discussions often classify <em>hypertriglyceridemia<\/em> (elevated Triglycerides) by context and cause. Common, clinically useful categorizations include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>By timing relative to meals<\/strong><\/li>\n<li><strong>Fasting Triglycerides:<\/strong> reflects baseline hepatic production and clearance of triglyceride-rich lipoproteins.<\/li>\n<li>\n<p><strong>Nonfasting (postprandial) Triglycerides:<\/strong> influenced by recent dietary fat and carbohydrate intake; may better reflect day-to-day exposure to remnant particles in some settings.<\/p>\n<\/li>\n<li>\n<p><strong>By severity (conceptual, not numeric)<\/strong><\/p>\n<\/li>\n<li><strong>Mild to moderate elevation:<\/strong> often associated with insulin resistance, obesity, diabetes, and lifestyle factors.<\/li>\n<li>\n<p><strong>Marked or very high elevation:<\/strong> raises concern for chylomicronemia physiology and pancreatitis risk, and may require urgent evaluation for secondary and genetic contributors.<\/p>\n<\/li>\n<li>\n<p><strong>By etiology<\/strong><\/p>\n<\/li>\n<li><strong>Primary (genetic) disorders:<\/strong> variants affecting lipoprotein lipase pathways or apolipoproteins can produce substantial elevations, sometimes from a young age.<\/li>\n<li>\n<p><strong>Secondary causes:<\/strong> common and clinically important; include uncontrolled diabetes, alcohol use, hypothyroidism, chronic kidney disease, liver disease, pregnancy, and medication effects.<\/p>\n<\/li>\n<li>\n<p><strong>By associated lipid pattern<\/strong><\/p>\n<\/li>\n<li><strong>Atherogenic dyslipidemia:<\/strong> elevated Triglycerides with low high-density lipoprotein cholesterol (HDL-C) and increased small, dense LDL particles; often seen with insulin resistance.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Relevant anatomy &amp; physiology<\/h2>\n\n\n\n<p>Triglyceride metabolism connects multiple organs and vascular beds relevant to cardiovascular health:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Intestine and chylomicrons<\/strong><\/li>\n<li>Dietary fats are packaged into <strong>chylomicrons<\/strong> in the small intestine.<\/li>\n<li>\n<p>Chylomicrons enter circulation and deliver Triglycerides to tissues, especially adipose tissue and skeletal muscle.<\/p>\n<\/li>\n<li>\n<p><strong>Liver and very-low-density lipoproteins (VLDL)<\/strong><\/p>\n<\/li>\n<li>The liver synthesizes and exports Triglycerides within <strong>VLDL<\/strong> particles.<\/li>\n<li>\n<p>Hepatic production increases with excess caloric intake, insulin resistance, and increased delivery of free fatty acids from adipose tissue.<\/p>\n<\/li>\n<li>\n<p><strong>Endothelium and lipoprotein lipase (LPL)<\/strong><\/p>\n<\/li>\n<li><strong>Lipoprotein lipase<\/strong> is anchored to capillary endothelium (notably in adipose and muscle).<\/li>\n<li>LPL hydrolyzes Triglycerides in chylomicrons and VLDL, releasing fatty acids for energy use or storage.<\/li>\n<li>\n<p>LPL activity is regulated by apolipoproteins (for example, apoC-II as an activator) and other proteins that modulate triglyceride clearance.<\/p>\n<\/li>\n<li>\n<p><strong>Remnant particles and the arterial wall<\/strong><\/p>\n<\/li>\n<li>After triglyceride removal, <strong>remnant particles<\/strong> (chylomicron remnants and intermediate-density lipoproteins) can be taken up by the liver.<\/li>\n<li>\n<p>If remnant clearance is impaired, these apoB-containing particles can interact with the arterial wall, contributing to inflammation and plaque development in coronary and other arteries.<\/p>\n<\/li>\n<li>\n<p><strong>Cardiovascular context<\/strong><\/p>\n<\/li>\n<li>Elevated Triglycerides commonly accompany endothelial dysfunction and systemic inflammation seen in metabolic disease.<\/li>\n<li>They often parallel other cardiology-relevant markers such as non-HDL cholesterol and apoB (when measured), which reflect atherogenic particle burden.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Pathophysiology or mechanism<\/h2>\n\n\n\n<p>Elevated Triglycerides typically reflect an imbalance between production and clearance of triglyceride-rich lipoproteins.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Increased production<\/strong><\/li>\n<li><strong>Insulin resistance<\/strong> promotes hepatic VLDL overproduction by increasing substrate (free fatty acids) delivery to the liver and altering hepatic lipid handling.<\/li>\n<li>Diet patterns high in refined carbohydrates or excess calories can increase de novo lipogenesis (fat creation) and VLDL output.<\/li>\n<li>\n<p>Alcohol can increase hepatic triglyceride synthesis and impair clearance in susceptible individuals.<\/p>\n<\/li>\n<li>\n<p><strong>Decreased clearance<\/strong><\/p>\n<\/li>\n<li>Reduced LPL activity (genetic or acquired) slows hydrolysis of circulating Triglycerides.<\/li>\n<li>\n<p>Certain conditions (poorly controlled diabetes, hypothyroidism, kidney disease) and medications can reduce triglyceride clearance or increase production.<\/p>\n<\/li>\n<li>\n<p><strong>Atherosclerosis link (why Triglycerides correlate with ASCVD)<\/strong><\/p>\n<\/li>\n<li>Triglyceride-rich lipoproteins themselves are large and may be less likely to enter the arterial wall than LDL, but their <strong>remnants<\/strong> can be atherogenic.<\/li>\n<li>Remnant particles often carry apoB and cholesterol, and can contribute to plaque formation and inflammation.<\/li>\n<li>\n<p>The relationship between Triglycerides and ASCVD risk is influenced by correlated metabolic factors (for example, diabetes and obesity), and the strength of association can vary by population and analytic method.<\/p>\n<\/li>\n<li>\n<p><strong>Pancreatitis mechanism (when Triglycerides are very high)<\/strong><\/p>\n<\/li>\n<li>Very high concentrations can be associated with chylomicronemia, increasing blood viscosity and promoting pancreatic microvascular injury and inflammation.<\/li>\n<li>The exact threshold and individual susceptibility vary by patient factors and clinical context.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical presentation or indications<\/h2>\n\n\n\n<p>Triglycerides are most often encountered as a laboratory finding rather than a symptom. Typical scenarios include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Routine lipid screening in primary care, preventive cardiology, or preoperative evaluation.<\/li>\n<li>Cardiovascular risk assessment in patients with hypertension, diabetes, obesity, or family history of premature ASCVD.<\/li>\n<li>Workup of suspected metabolic syndrome or insulin resistance (often alongside HDL-C, fasting glucose or hemoglobin A1c, and waist circumference).<\/li>\n<li>Evaluation of fatty liver disease risk patterns (clinical interpretation varies by clinician and case).<\/li>\n<li>Investigation of <strong>marked hypertriglyceridemia<\/strong>, especially when there is:<\/li>\n<li>A history of pancreatitis<\/li>\n<li>Eruptive xanthomas (yellowish papules) or lipemia retinalis (rare, typically with very high levels)<\/li>\n<li>Family history suggesting an inherited lipid disorder<\/li>\n<li>Medication review when Triglycerides rise after starting drugs known to affect lipids (examples depend on the medication class and patient factors).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Diagnostic evaluation &amp; interpretation<\/h2>\n\n\n\n<p>Clinicians interpret Triglycerides in the context of overall cardiometabolic health and the full lipid profile.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>How Triglycerides are measured<\/strong><\/li>\n<li>Usually obtained as part of a standard lipid panel.<\/li>\n<li>\n<p>Testing may be done fasting or nonfasting depending on local protocol and clinical question. Nonfasting values can be informative but may be more variable after meals.<\/p>\n<\/li>\n<li>\n<p><strong>How results are interpreted (general patterns)<\/strong><\/p>\n<\/li>\n<li>Persistent elevation suggests increased triglyceride-rich lipoproteins and often correlates with insulin resistance and higher cardiometabolic risk.<\/li>\n<li>A single elevated value can reflect recent diet, alcohol intake, acute illness, uncontrolled diabetes, or laboratory variability; repeat assessment may be considered depending on context.<\/li>\n<li>\n<p>Marked elevation raises concern for pancreatitis risk and for disorders affecting LPL pathways or secondary contributors.<\/p>\n<\/li>\n<li>\n<p><strong>Interaction with other lipid measures<\/strong><\/p>\n<\/li>\n<li>When Triglycerides are high, calculated LDL-C can become less reliable because common equations assume a typical relationship between Triglycerides and VLDL cholesterol.<\/li>\n<li>Clinicians may emphasize <strong>non-HDL cholesterol<\/strong> (total cholesterol minus HDL-C) or consider <strong>apoB<\/strong> (if available) to estimate atherogenic particle burden.<\/li>\n<li>\n<p>Direct LDL-C measurement may be used in some settings when calculation is unreliable; practices vary by laboratory and clinician.<\/p>\n<\/li>\n<li>\n<p><strong>Evaluation for secondary causes<\/strong><\/p>\n<\/li>\n<li>A targeted history often reviews diet pattern, alcohol use, recent weight change, pregnancy, and medications.<\/li>\n<li>\n<p>Common laboratory evaluation may include glucose or hemoglobin A1c, thyroid-stimulating hormone (TSH), liver enzymes, and kidney function. The specific workup varies by protocol and patient factors.<\/p>\n<\/li>\n<li>\n<p><strong>When to consider genetic etiologies<\/strong><\/p>\n<\/li>\n<li>Very high Triglycerides, early onset, recurrent pancreatitis, or strong family history may prompt consideration of inherited disorders.<\/li>\n<li>The extent of genetic testing and specialist referral varies by clinician and case.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Management overview (General approach)<\/h2>\n\n\n\n<p>Management of elevated Triglycerides is typically individualized and based on overall cardiovascular risk, severity of elevation, and underlying cause. This section is educational and not medical advice.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Address secondary contributors<\/strong><\/li>\n<li>Optimizing glycemic control in diabetes, treating hypothyroidism, reviewing medication contributors, and moderating alcohol intake (when relevant) can meaningfully affect Triglycerides.<\/li>\n<li>\n<p>Because causes often coexist, clinicians frequently take a stepwise approach and reassess after changes.<\/p>\n<\/li>\n<li>\n<p><strong>Lifestyle-focused strategies<\/strong><\/p>\n<\/li>\n<li>Nutrition: approaches often aim to reduce excess calories, refined carbohydrates, and alcohol; dietary fat quality and overall pattern matter, and plans vary by patient context.<\/li>\n<li>Physical activity: improved insulin sensitivity can lower Triglycerides over time.<\/li>\n<li>\n<p>Weight management: in many patients, weight reduction improves Triglycerides and related metabolic markers.<\/p>\n<\/li>\n<li>\n<p><strong>Pharmacologic therapy in cardiology context<\/strong><\/p>\n<\/li>\n<li><strong>Statins<\/strong> are commonly used for ASCVD risk reduction and may modestly lower Triglycerides while primarily targeting LDL-C and apoB-containing particles.<\/li>\n<li><strong>Triglyceride-lowering agents<\/strong> (for example, fibrates or prescription omega-3 fatty acids) may be considered in selected patients, particularly with marked elevations or specific risk profiles. Choice depends on comorbidities, drug interactions, and clinician judgment.<\/li>\n<li><strong>Icosapent ethyl<\/strong> (a purified eicosapentaenoic acid formulation) is used in some higher-risk patients with elevated Triglycerides as part of residual risk management, depending on eligibility and local practice.<\/li>\n<li>\n<p>Other therapies exist or are emerging (for example, agents targeting apoC-III or angiopoietin-like protein 3 pathways), but availability and indications vary by country, protocol, and patient factors.<\/p>\n<\/li>\n<li>\n<p><strong>Care pathway integration<\/strong><\/p>\n<\/li>\n<li>In preventive cardiology, Triglycerides guide broader risk discussions and selection of lipid-focused therapies.<\/li>\n<li>In acute care settings, very high Triglycerides may be addressed alongside evaluation for pancreatitis or other metabolic decompensation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Complications, risks, or limitations<\/h2>\n\n\n\n<p>Common complications, risks, and limitations related to Triglycerides include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Atherosclerotic risk correlation<\/strong><\/li>\n<li>\n<p>Elevated Triglycerides often track with other atherogenic abnormalities; isolating their independent contribution can be complex and varies by patient profile and analytic approach.<\/p>\n<\/li>\n<li>\n<p><strong>Pancreatitis risk with marked elevation<\/strong><\/p>\n<\/li>\n<li>\n<p>Very high Triglycerides are associated with pancreatitis risk; the degree of risk varies by individual susceptibility, underlying cause, and concurrent exposures.<\/p>\n<\/li>\n<li>\n<p><strong>Laboratory and interpretation limitations<\/strong><\/p>\n<\/li>\n<li>Triglycerides show higher biologic variability than some other lipid measures and are influenced by recent food intake and alcohol.<\/li>\n<li>\n<p>High Triglycerides can reduce the accuracy of calculated LDL-C, which may affect treatment decisions unless alternative metrics are considered.<\/p>\n<\/li>\n<li>\n<p><strong>Medication-related considerations (context-dependent)<\/strong><\/p>\n<\/li>\n<li>Fibrates can be associated with muscle-related adverse effects, particularly when combined with certain statins, and may affect gallbladder or liver-related parameters in some patients.<\/li>\n<li>Omega-3 fatty acid preparations can cause gastrointestinal side effects; bleeding risk considerations may apply in patients on anticoagulants or antiplatelet therapy (clinical significance varies).<\/li>\n<li>Niacin is less commonly used in many practices due to tolerability and outcome evidence considerations; usage varies by clinician and case.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Prognosis &amp; follow-up considerations<\/h2>\n\n\n\n<p>The prognosis associated with elevated Triglycerides depends on the underlying driver (for example, insulin resistance vs a genetic clearance disorder), the degree and persistence of elevation, and the patient\u2019s overall cardiometabolic risk profile.<\/p>\n\n\n\n<p>For cardiovascular outcomes, Triglycerides are typically interpreted as part of a larger risk framework that includes LDL-C or apoB-containing particle burden, blood pressure, glycemic status, smoking, kidney function, and family history. In many patients, improvement in metabolic health (weight, insulin sensitivity, diabetes control) improves Triglycerides and may also improve other risk markers.<\/p>\n\n\n\n<p>Follow-up commonly involves repeat lipid testing to assess response to lifestyle and\/or medication changes, along with monitoring for secondary causes. In cases of marked hypertriglyceridemia or pancreatitis history, follow-up may be more frequent and may involve lipid specialists; specific intervals vary by protocol and patient factors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Triglycerides Common questions (FAQ)<\/h2>\n\n\n\n<p><strong>Q: What are Triglycerides in plain language?<\/strong><br\/>\nTriglycerides are fats carried in the bloodstream and stored in fat tissue for energy. They come from dietary fat and from fat made in the liver, especially when calorie intake exceeds needs. Clinicians measure Triglycerides on a lipid panel to better understand metabolic and cardiovascular risk patterns.<\/p>\n\n\n\n<p><strong>Q: How are Triglycerides different from cholesterol?<\/strong><br\/>\nTriglycerides mainly reflect energy storage and transport, while cholesterol is a structural molecule used in cell membranes and hormone synthesis. Both travel in lipoproteins, but they represent different components of those particles. In cardiology, cholesterol metrics often focus on atherogenic particle burden, while Triglycerides add context about triglyceride-rich lipoproteins and metabolic health.<\/p>\n\n\n\n<p><strong>Q: Does a high Triglycerides result mean someone has heart disease?<\/strong><br\/>\nNot by itself. Elevated Triglycerides can be a marker of increased cardiometabolic risk, but heart disease diagnosis depends on symptoms, examination, and other testing (for example, electrocardiogram, imaging, and additional labs). Clinicians interpret Triglycerides alongside the full risk profile.<\/p>\n\n\n\n<p><strong>Q: Should Triglycerides be checked fasting or nonfasting?<\/strong><br\/>\nBoth approaches are used. Nonfasting Triglycerides may reflect typical day-to-day exposure after meals, while fasting values can reduce meal-related variability and may be preferred when Triglycerides are markedly elevated or when calculated LDL-C accuracy is important. The choice varies by clinician, laboratory protocol, and clinical question.<\/p>\n\n\n\n<p><strong>Q: Can Triglycerides be temporarily high?<\/strong><br\/>\nYes. Recent high-calorie intake, alcohol use, acute illness, uncontrolled diabetes, and some medications can raise Triglycerides transiently. Because of this variability, clinicians may repeat testing or look for reversible contributors when results are unexpected.<\/p>\n\n\n\n<p><strong>Q: What are common causes of elevated Triglycerides?<\/strong><br\/>\nCommon contributors include insulin resistance, type 2 diabetes, obesity, excess refined carbohydrates, alcohol use, hypothyroidism, kidney disease, and certain medications. Genetic lipid disorders can also play a role, especially when elevations are marked or occur early in life. Often, more than one factor is present.<\/p>\n\n\n\n<p><strong>Q: Why do very high Triglycerides raise concern about pancreatitis?<\/strong><br\/>\nVery high Triglycerides can reflect accumulation of large triglyceride-rich particles (such as chylomicrons) that may promote pancreatic inflammation. Not everyone with high Triglycerides develops pancreatitis, and susceptibility varies by cause and patient factors. Clinicians take this possibility seriously because pancreatitis can be severe.<\/p>\n\n\n\n<p><strong>Q: How do clinicians decide what to do about elevated Triglycerides?<\/strong><br\/>\nThey usually consider the overall cardiovascular risk, how high and how persistent the Triglycerides are, and whether secondary causes are present. Management often starts with addressing reversible contributors and optimizing overall risk reduction (such as LDL-C\u2013focused therapy when indicated). Additional triglyceride-lowering medications may be considered in selected scenarios.<\/p>\n\n\n\n<p><strong>Q: How do Triglycerides affect the rest of the lipid panel?<\/strong><br\/>\nWhen Triglycerides are elevated, calculated LDL-C can become less reliable, which may change how clinicians interpret the lipid profile. In that setting, non-HDL cholesterol or apoB (if measured) can help estimate atherogenic particle burden. The best approach depends on the lab methods and the clinical situation.<\/p>\n\n\n\n<p><strong>Q: What follow-up testing is typical after an abnormal Triglycerides result?<\/strong><br\/>\nFollow-up often includes repeating the lipid panel and checking for secondary causes (for example, glucose or hemoglobin A1c and thyroid testing), depending on the context. Monitoring plans vary by clinician and patient factors, including baseline risk and whether medication changes were made. In complex cases, referral to a lipid specialist may be considered.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Triglycerides are a type of lipid (fat) made of glycerol plus three fatty acids. They are both a circulating biomarker measured on a lipid panel and a stored energy source in adipose (fat) tissue. In cardiology, Triglycerides are commonly encountered during cardiovascular risk assessment and metabolic evaluation. They are discussed alongside cholesterol fractions (low-density lipoprotein cholesterol and high-density lipoprotein cholesterol) in dyslipidemia.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-554","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/comments?post=554"}],"version-history":[{"count":0,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/554\/revisions"}],"wp:attachment":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/media?parent=554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/categories?post=554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/tags?post=554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}